Suppr超能文献

一种基于DNA熔解温度的新型检测方法,用于多重鉴定严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和甲型/乙型流感病毒。

A novel assay based on DNA melting temperature for multiplexed identification of SARS-CoV-2 and influenza A/B viruses.

作者信息

Gao Peng, Fan Yanyan, Kong Xiaomu, Zhang Rui, Chen Lida, Jiang Yongwei, Liu Yi, Zhao Meimei, Deng Guoxiong, Cao Yongtong, Ma Liang

机构信息

Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.

Laboratory of Clinical Microbiology and Infectious Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.

出版信息

Front Microbiol. 2023 Dec 19;14:1249085. doi: 10.3389/fmicb.2023.1249085. eCollection 2023.

Abstract

INTRODUCTION

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses can cause respiratory illnesses with similar clinical symptoms, making their differential diagnoses challenging. Additionally, in critically ill SARS-CoV-2-infected patients, co-infections with other respiratory pathogens can lead to severe cytokine storm and serious complications. Therefore, a method for simultaneous detection of SARS-CoV-2 and influenza A and B viruses will be clinically beneficial.

METHODS

We designed an assay to detect five gene targets simultaneously via asymmetric PCR-mediated melting curve analysis in a single tube. We used specific probes that hybridize to corresponding single-stranded amplicons at low temperature and dissociate at high temperature, creating different detection peaks representing the targets. The entire reaction was conducted in a closed tube, which minimizes the risk of contamination. The limit of detection, specificity, precision, and accuracy were determined.

RESULTS

The assay exhibited a limit of detection of <20 copies/μL for SARS-CoV-2 and influenza A and <30 copies/μL for influenza B, with high reliability as demonstrated by a coefficient of variation for melting temperature of <1.16% across three virus concentrations. The performance of our developed assay and the pre-determined assay showed excellent agreement for clinical samples, with kappa coefficients ranging from 0.98 (for influenza A) to 1.00 (for SARS-CoV-2 and influenza B). No false-positive, and no cross-reactivity was observed with six common non-influenza respiratory viruses.

CONCLUSION

The newly developed assay offers a straightforward, cost-effective and nucleic acid contamination-free approach for simultaneous detection of the SARS-CoV-2, influenza A, and influenza B viruses. The method offers high analytical sensitivity, reliability, specificity, and accuracy. Its use will streamline testing for co-infections, increase testing throughput, and improve laboratory efficacy.

摘要

引言

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和流感病毒可引起具有相似临床症状的呼吸道疾病,这使得它们的鉴别诊断具有挑战性。此外,在重症SARS-CoV-2感染患者中,与其他呼吸道病原体的合并感染可导致严重的细胞因子风暴和严重并发症。因此,一种同时检测SARS-CoV-2和甲型及乙型流感病毒的方法将具有临床益处。

方法

我们设计了一种检测方法,通过单管中的不对称PCR介导的熔解曲线分析同时检测五个基因靶点。我们使用特异性探针,其在低温下与相应的单链扩增子杂交,并在高温下解离,产生代表靶点的不同检测峰。整个反应在封闭管中进行,这将污染风险降至最低。确定了检测限、特异性、精密度和准确度。

结果

该检测方法对SARS-CoV-2和甲型流感的检测限<20拷贝/μL,对乙型流感的检测限<30拷贝/μL,在三种病毒浓度下熔解温度的变异系数<1.16%,证明具有高可靠性。我们开发的检测方法与预定检测方法对临床样本的检测性能显示出极好的一致性,kappa系数范围从0.98(甲型流感)到1.00(SARS-CoV-2和乙型流感)。未观察到假阳性,并且与六种常见的非流感呼吸道病毒无交叉反应。

结论

新开发的检测方法为同时检测SARS-CoV-2、甲型流感和乙型流感病毒提供了一种简单、经济高效且无核酸污染的方法。该方法具有高分析灵敏度、可靠性、特异性和准确度。其应用将简化合并感染的检测,提高检测通量,并改善实验室效率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/10762780/86288655ae63/fmicb-14-1249085-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验